A Phase 2 interventional study of RAP-219 in Focal Epilepsy, Epilepsy and Refractory Focal Epilepsy, sponsored by Rapport Therapeutics Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Rapport Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 63rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2025, is one of 23 in phase 2, reaches primary completion later than 14 of the 22 other live ones, and was the 96th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
University of California, San Francisco · Sites in United States
Ages 21–65
University of California, Davis · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
Rapport Therapeutics Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Rapport Therapeutics Inc. has 4 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
This is a multi-center, open-label study to evaluate the long-term safety, tolerability, pharmacokinetics, pharmacodynamics and antiseizure activity of RAP-219 in adult participants with refractory focal seizures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RAP-219
Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: From the start of RAP-219 treatment through 8 weeks after last dose, up to Week 112
Percent change in clinical seizure frequency
Group median percent change in clinical seizure frequency per 28-day period as reported in a clinical seizure diary
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Clinical seizure 25%, 50%, 75%, and 100% responder proportions
Proportion of participants with at least 25%, 50%, 75%, or with 100% reduction in clinical seizure frequency per 28-day period as reported in a clinical seizure diary
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Change in clinical seizure-free day frequency
Group median change in clinical seizure-free day frequency per 28-day period as reported in a clinical seizure diary
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Longest clinical seizure-free interval
Duration, in days, of the longest continuous period of clinical seizure-free days per period as reported in a clinical seizure diary
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Time to pre-randomization clinical seizure count
Duration, in days, between the beginning of the open-label treatment period and the nth clinical seizure, where n is the number of clinical seizures per 28-day period during the prospective pre-treatment baseline period, as reported in a clinical seizure diary
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
RNS long episode 30%, 50%, 75% or with 100% responder proportions
Proportion of participants with at least 30%, 50%, 75%, and 100% reduction in long episodes per 28-day period as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Percent change in RNS long episode frequency
Group median percent change in long episode frequency per 28-day period as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Change in RNS long episode-free day frequency
Group median change in long episode-free day frequency per 28-day period as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Longest RNS long episode-free interval
Duration, in days, of the longest continuous period of long episode-free days per period as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Time to pre-randomization long episode count
Duration, in days, between the beginning of the open-label treatment period and the mth long episode, where m is the number of long episodes per 28-day period during the pre-treatment baseline period, as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Percent change in RNS estimated electrographic seizure frequency
Group median percent change in estimated electrographic seizure frequency per 28-day period as recorded by the RNS® System
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Clinical Global Impression of Change (CGI-C) responder count and proportions
Count and proportion of participants with any improvement (minimally improved, much improved, or very much improved) or clinically meaningful improvement (much improved or very much improved) as reported on the Clinical Global Impression of Change (CGI-C) scale
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Patient Global Impression of Change [PGI-C] responder count and proportions
Count and proportion of participants with any improvement (minimally improved, much improved, or very much improved) or clinically meaningful improvement (much improved or very much improved) as reported on the Patient Global Impression of Change (PGI-C) scale
Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.
Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RAP-219
Rapport Therapeutics Inc.